A translational strategy employing physiologically based modelling to predict the pharmacological active dose of RO7119929, an oral prodrug of a targeted cancer immunotherapy TLR7 agonist
Sign Up to like & getrecommendations! Published in 2022 at "Xenobiotica"
DOI: 10.1080/00498254.2022.2116368
Abstract: Abstract RO7119929 is being developed as an orally administered prodrug of the TLR7-specific agonist and active drug, RO7117418, for the treatment of patients with solid tumours. In this publication, we present a case study wherein… read more here.
Keywords: pharmacological active; active dose; prodrug; active drug ... See more keywords